Blog

Future Fifty: joining forces to drive forward positive change

We are immensely excited and proud to have been selected for Tech Nation's 2020 Future Fifty cohort, alongside 28 fellow UK tech trailblazers.

It’s been an honour witnessing the impressive growth of the UK tech scene over the past decade. Before joining Benevolent in 2018, I spent five years helping the Government harness the potential of technology: maximising the growth of the digital economy and serving as the UK’s first Minister for Internet Security and Safety. In the years since thousands of fast-growth startups have flourished in Britain, each founded with the hope that our world can be improved through technology. It is gratifying to see that so many fellow members of this year's Future Fifty cohort are inspired and committed to the dream of ‘what can be’, and are channelling this into innovations that fundamentally change things for the better.

Tech Nation’s Future Fifty was founded with the purpose of bringing together the country’s most successful tech businesses to build a powerful network of peers. With the help of the tech community, the programme supports companies in achieving their global ambitions, creating jobs and opportunities across the UK, and inspiring the next generation of tech entrepreneurs, founders and businesses. Community and knowledge sharing helped establish the UK as one of the leading locations to start, nurture and grow or tech-enabled disruptive businesses, with a number of high profile success stories listing on the LSE.

In these challenging times, we have seen the global scientific community mobilise to respond to the deadly disease ravaging our planet, and have once again witnessed how community serves as a powerful vehicle for transformation and hope. Finally, as UK tech journeys into a new phase in a post-Brexit world, it is more important than ever that we join forces with like-minded industry experts to drive forward towards a more purposeful future.

I am inspired by the uncompromising determination and passion of the talented team we have assembled here at Benevolent.  We are united by our mission to push the boundaries of technology and to use AI and machine learning to develop more effective medicines for patients in areas of significant unmet need. Experts from diverse technology and scientific disciplines such as machine learning, drug discovery and engineering work together towards a common goal: a future in which no disease goes untreated. Having Future Fifty by our side for the journey ahead will undoubtedly help us further deliver against this vision.

The saying goes that the whole is greater than the sum of its parts. This is no doubt true of the UK tech scene: together, we make up the number-three tech startup ecosystem in the world. Together, we have secured our place at the heart of the biggest story of 21st-century growth and promise. Together, we are working on solutions to pressing global challenges that will impact quality of life and improve society for all.

Joanna Shields, CEO

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021